ArticleCell2018
NKG2A, a New Kid on the Immune Checkpoint Block.
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 98 citations in OpenAlex.
- TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.Journal for immunotherapy of cancer · 2020Trial
- Uveal melanoma: A review of current treatment limitations and the emerging therapeutic potential of natural killer cells.The Journal of investigative dermatology · 2026Review
- Extraordinary diversity of antiviral immune-related gene families across 38 bat species.BMC biology · 2026Article
- Comparative two-dimensional NKG2A/CD94 cell membrane chromatography for targeted screening immune checkpoint inhibitors.Journal of pharmaceutical analysis · 2026Article
- Targeting MHC-E as a new strategy for vaccines and immunotherapeutics.Nature reviews. Immunology · 2026Review
- T-cell exhaustion and antibody response in SARS-CoV-2 vaccine recipients.Revista peruana de medicina experimental y salud publica · 2025Article
- Human iPSC-derived NK cells armed with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complex enhance anti-solid tumor activity.Stem cell research & therapy · 2025Article
- Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential.Experimental hematology & oncology · 2025Review
- KLRD1 (CD94): A Prognostic Biomarker and Therapeutic Candidate in Head and Neck Squamous Cell Carcinoma.Journal of Cancer · 2025Article
- A novel NKG2A alpaca nanobody targeting immune checkpoint blockade for the treatment of malignant melanoma.Frontiers in veterinary science · 2025Article
- Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy.Journal for immunotherapy of cancer · 2024Review
- MHC1/LILRB1 axis as an innate immune checkpoint for cancer therapy.Frontiers in immunology · 2024Review
- Prognostic value of immunosuppression scores in patients with esophageal squamous cell carcinoma: a multicenter study.Frontiers in immunology · 2024Article
- High-grade serous ovarian carcinoma, the "Achiles' hill" for clinicians and molecular biologists: a molecular insight.Molecular biology reports · 2023Review
- Natural killer cells strengthen antitumor activity of cisplatin by immunomodulation and ameliorate cisplatin-induced side effects.International urology and nephrology · 2023Article
- Non-Classical HLA Class 1b and Hepatocellular Carcinoma.Biomedicines · 2023Review
- Immune-checkpoint inhibitor therapy response evaluation using oncophysics-based mathematical models.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Review
- Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors.Biology · 2023Review
- Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine targeting of a novel immune checkpoint, NKG2A, that can be expressed on both NK cells and on CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.